Veeva：2024年在当今数字世界中实现卓越发布的4个步骤报告（英文版）

The first six months after launch have historically determined peak sales of a new life sciences product. But as the industry quickly learned after the COVID-19 outbreak, that’s not the case during a pandemic. A study of 86 launches between February and August 2020 found that every single one was “disrupted” through delays, lost revenues, or both.1 In fact, analysts’ expectations of the value of the drugs in question decreased 9%—equal to a $10 billion loss globally. This immediate disruption